J. Pers. Med. 2013, 3(2), 111-123; doi:10.3390/jpm3020111
Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
1
Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, MD 20814, USA
2
EJS Health Solutions, LLC, 1653 Pennfield Drive Thorofare, West Deptford, NJ 08086, USA
3
Biocerna, LLC, Gaithersburg, MD 20879, USA
4
Opus Three, LLC, Gaithersburg, MD 20878, USA
*
Author to whom correspondence should be addressed.
Received: 17 April 2013 / Revised: 24 May 2013 / Accepted: 4 June 2013 / Published: 10 June 2013
View Full-Text
|
Download PDF [427 KB, uploaded 10 June 2013]
Abstract
We surveyed 10,303 United States physicians on where they obtain pharmacogenomic testing information. Thirty-nine percent indicated that they obtained this from drug labeling. Factors positively associated with this response included older age, postgraduate instruction, using other information sources, regulatory approval/ recommendation of testing, reliance on labeling for information, and perception that patients have benefited from testing. Physicians use pharmacogenomic testing information from drug labeling, highlighting the importance of labeling information that is conducive to practice application. View Full-TextKeywords:
pharmacogenomics; physician; drug labeling; survey
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Stanek, E.J.; Sanders, C.L.; Frueh, F.W. Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information. J. Pers. Med. 2013, 3, 111-123.
Related Articles
Article Metrics
Comments
[Return to top]
J. Pers. Med.
EISSN 2075-4426
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert